{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-057490","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.453922+00:00","generated_at":"2026-06-25T22:18:51.978077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocular Therapeutix Q1 DEXTENZA revenue $12.5M (+87% YoY); net loss $12.5M; guides FY22 product rev $55-60M","bullets":["DEXTENZA net product revenue $12.5M in Q1 2022, up 87% from $6.7M in Q1 2021.","Net loss $12.5M ($0.16 basic loss per share) vs. net income $3.1M in Q1 2021; includes $7M non-cash derivative liability adjustment.","Cash and equivalents $145.4M as of March 31, 2022; company believes sufficient through 2023.","Guides FY2022 DEXTENZA revenue $55-60M (26-38% growth); expands commercial team with VP Steve Meyers for office setting.","OTX-TKI Phase 1 fully enrolled, six-month data expected Q3 2022; OTX-TIC Phase 2 dosing began, triggering $2M milestone from AffaMed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-057490","json":"https://secwatch.observer/filing/0001104659-22-057490.json","markdown":"https://secwatch.observer/filing/0001104659-22-057490.md","text":"https://secwatch.observer/filing/0001104659-22-057490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/0001104659-22-057490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/tm2214885d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:18:51.978077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}